Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing or treating keloids or hypertrophic scars

a technology for hypertrophic scars and keloids, applied in the field of compositions for preventing or treating keloids or hypertrophic scars, can solve the problems of hypertrophic scars or keloids, hypertrophic scars or keloids, and limited methods, and achieve accurate diagnosis of hypertrophic scars, inhibiting the expression and activity of proteins, and preventing or treating hypertrophic scars.

Inactive Publication Date: 2021-12-16
TEGO SCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a protein that is associated with abnormal collagen formation in wounds which can lead to keloid or hypertrophic scars. By identifying this protein, the accuracy of diagnosing these scars can be improved using the corresponding protein and its gene. Additionally, a material can be provided that inhibits the expression and activity of this protein, which can be used to alleviate and treat keloid or hypertrophic scars.

Problems solved by technology

When a dermal layer located deep in the skin is damaged due to surgery or trauma, collagen needed to maintain tension of the skin proliferates excessively in the dermal layer so that the collagen emerges from the thin skin even after a wound has healed, leaving a wound-healed scar in the skin, which is referred to “normal scar.” This appears as a result of wound healing, but hypertrophic scars or keloids may appear because fibrous tissues grow abnormally in a compact manner when the skin has a dysfunction in properly regulating and inhibiting a wound healing process.
There have been various attempts to treat the hypertrophic scars or keloids, including surgical therapy, radiotherapy, steroid therapy, occlusive dressing with silicone gel, laser therapy, and the like, but these methods have limited effects.
It was known that hypertrophic scars or keloids are formed due to the excessive accumulation of collagen when movement of cells is overactivated during a wound healing process, or when the collagen is formed excessively or is not degraded normally as the cells and capillary vessels proliferate abnormally.
There is little information on biomarkers that participate in formation of collagen, which excessively accumulates during the wound healing process, and proliferation of cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating keloids or hypertrophic scars
  • Composition for preventing or treating keloids or hypertrophic scars

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043]Preparation of Human Skin Fibroblasts, Normal Tissues, and Hypertrophic Scar Tissues

[0044]Skin tissues used in this experiment were obtained from a total of three patients, and an immunohistochemical (IHC) experiment was conducted using male and female normal tissues and scar tissues. Then, an effect of siRNA transformation was observed using primary fibroblast cells derived from each of the tissues.

[0045]A tissue was washed with 70% ethanol, and fats were removed by trimming. Then, the tissue was chopped to separate a tissue for the MC experiment. The remaining tissue was further trimmed, and then chopped. A mixed solution including collagenase, trypsin, and EDTA was added to the tissue, and the cells were isolated by centrifugation at 37° C. and 100 rpm. The isolated cells were cultured in an F12 medium supplanted with 10% fetal bovine serum (FBS) and gentamycin.

[0046]Comparison of Expression of Candidate Proteins Via Immunohistochemical (IHC) Experiment on Hypertrophic Scar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
tensionaaaaaaaaaa
Northern blottingaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for preventing or treating keloids or hypertrophic scars.BACKGROUND ART[0002]When a dermal layer located deep in the skin is damaged due to surgery or trauma, collagen needed to maintain tension of the skin proliferates excessively in the dermal layer so that the collagen emerges from the thin skin even after a wound has healed, leaving a wound-healed scar in the skin, which is referred to “normal scar.” This appears as a result of wound healing, but hypertrophic scars or keloids may appear because fibrous tissues grow abnormally in a compact manner when the skin has a dysfunction in properly regulating and inhibiting a wound healing process. The hypertrophic scars are different from the keloids in that the hypertrophic scars do not extend beyond a wound area and tend to gradually disappear over time, but the keloids grow wider than a damaged area and penetrate into a normal skin over time. There have been various a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/113G01N33/68A61K31/713A61K31/7105
CPCC12N15/113G01N33/6881G01N33/6893G01N2500/04A61K31/7105G01N2800/20A61K31/713C12Q1/6883C12Q2600/136C12Q2600/158C12N2310/14A61K31/7088A61P17/02
Inventor JEON, SAEWHACHUNG, HO YUNOH, NA RAKIM, YUN HEEHAN, JIK HYONMOON, HYUN AH
Owner TEGO SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products